
*** RX REPORT ***

RECEPTION OK

TX/RX NO	9556	
CONNECTION TEL		202 393 5350
SUBADDRESS		
CONNECTION ID		
ST. TIME	10/04 13:06	
USAGE T	02'46	
PGS.	7	
RESULT	OK	

OFFICIAL PR 10/4/00

ATTY. DKT. NO. P60953US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

JENSEN et al.

Via Facsimile
703-308-0294

Serial No.: 09/060,294

Art Unit 1646

Filed: April 15, 1998

Examiner David Romeo

For: MODIFIED TNF- α MOLECULES, DNA ENCODING SUCH AND VACCINES
COMPRISING SUCH MODIFIED TNF- α AND DNA

TRANSMITTAL

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:


Transmitted herewith via facsimile is Supplemental Amendment in the above-captioned application.

XX No fee is considered for filing the instant paper.

XX If a Petition for Extension of Time is necessary and the Petition and/or the check is not enclosed, this will act as the Petition and applicant herewith petitions the Commissioner to extend the time for response and charge any fees necessary under 37 CFR 1.17 (a)-(d) to Deposit Account No. 06-1358. The Commissioner is also authorized to charge payment of any other additional fees associated with this communication or credit any overpayment to Deposit Account No. 06-1358.

JACOBSON, PRICE, HOLMAN & STERN, PLLC
400 Seventh Street, N. W.
Washington, D.C. 20004-2201
Atty. Dkt. No.: P60953US1
Date: October 4, 2000
HCW/WEP

By:


Harvey B. Jacobson, Jr.
Registration No. 20,851

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

F15
10-5-00

In re the Application of:

JENSEN et al

Art Unit 1646

Serial No.: 09/060,294

Examiner D. Romeo

Filed: April 15, 1998

For: MODIFIED TNF- α MOLECULES, DNA ENCODING SUCH AND VACCINES
COMPRISING SUCH MODIFIED TNF- α AND DNA

SUPPLEMENTAL AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

The instant amendment supplements the amendment filed 20 July 2000, in response to the
Office Action mailed January 20, 2000.

IN THE CLAIMS

Cancel claims 1, 2, 4, 16, 19, and 26-49, without prejudice or disclaimer, and add the
following replacement claims.

50. A human TNF α molecule capable of raising neutralizing antibodies towards
unmodified human TNF α following administration of said TNF α to a human host, wherein one or
more peptide fragments of the human TNF α molecule has been substituted by one or more peptides
containing immunodominant T cell epitopes or a truncated form of said molecule containing the
immunodominant epitope and one or both flanking regions of the unmodified human TNF α -
molecule comprising at least one TNF α B cell epitope, wherein the substitution introduces a change
in the amino acid sequence of any one of the strands of the front β -sheet, in any one of the
connecting loops, or in any one of the B', I, or D strands of the back β -sheet.